CDMO - November 2, 2016
Recipharm invests in its Italian API facility
Recipharm has announced an investment of over €1.2 million to enhance its small scale GMP active pharmaceutical ingredient (API) development and manufacturing capabilities in Paderno Dugnano, Italy. The investment, which is in response to growing demand for Recipharm’s custom synthesis and early phase API manufacturing capabilities, has seen the opening of a new GMP kilo […]
CDMO - October 19, 2016
Recipharm to open new GLP bioanalysis laboratory in Uppsala
Recipharm has announced a 5 million SEK investment into a new GLP (Good Laboratory Practice) compliant bioanalysis laboratory at its development facility in Uppsala, Sweden, in response to growing customer demand. The investment will see the opening of a 500 square metre purpose-built facility in November 2016, which will become the largest GLP bioanalysis laboratory of […]
Acquisition - April 16, 2016
Recipharm creates global CDMO through new acquisitions
Swedish CDMO Recipharm continues to expand. Most recently the company acquired Kemwell’s pharmaceutical CDMO businesses. In February Recipharm acquired privately owned Italian CDMO Mitim, adding important technology in the filling of injectable beta lactams with sales to the US and European markets. The transaction is valued at an enterprise value of EUR 68 million. The […]
Acquisition - February 24, 2016
Recipharm to acquire Mitim Srl for SEK 640 million
Recipharm AB announces that it has entered into an agreement to acquire Italian CDMO, Mitim Srl adding scale and capabilities to the group. Mitim is currently owned by a private Italian family and is specialised in the filling of injectable beta lactam products. It is located in Brescia close to Recipharm’s existing operations in Northern Italy. Highlights • Adds […]
CDMO - February 19, 2016
Recipharm makes €40m investment
Recipharm will invest €40m over the next three years to ensure state of-the-art solutions for serialisation processes. The move by the company comes as the announcement of the EU Falsified Medicines Directive (EUFMD) Safety Features Delegated Regulation is released. This means that the serialisation of licensed drug products will be a legal requirement for companies in the EU […]
Agreement - January 27, 2016
Curida signs agreement with Serviceproduksjon
Norwegian CDMO Curida has signed a framework-agreement with Serviceproduksjon, a subsidary to the Norwegian Pharmace Association. The agreement entails validation of a chemical analytical method for use in analysis of tablets and routine analysis of the particular drug. “Serviceproduksjon received offers from three other contract laboratories and chose Curida based on competency, competitive pricing and […]
